DOI: https://doi.org/10.1530/EJE-21-0479

 European Journal of Endocrinology

The Journal of Clinical Endocrinology & Metabolism, dgab557, 

https://doi.org/10.1210/clinem/dgab557

Published: 29 July 2021

Abstract

Context

Coronavirus disease 2019 (COVID-19) is a proinflammatory and prothrombotic condition, but its impact on adrenal function has not been adequately evaluated.

Case report

ESPEN GUIDELINE| VOLUME 40, ISSUE 7, P4745-4761, JULY 01, 2021

DOI:https://doi.org/10.1016/j.clnu.2021.03.031

Published: August 06, 2021

DOI:https://doi.org/10.1016/S0140-6736(21)01443-4

DOI:https://doi.org/10.1016/j.clnu.2021.05.006

Bridget M. Kuehn

Originally published19 Jul 2021

https://doi.org/10.1161/CIRCULATIONAHA.121.055711

The Journal of Clinical Endocrinology & Metabolism, dgab468, 

https://doi.org/10.1210/clinem/dgab468

Published: 29 June 2021

Abstract

Context

While adrenal adenomas have been linked with cardiovascular morbidity in convenience samples of patients from specialized referral centers, large-scale population-based data are lacking.

Objective

Summary

Background

Type 1 diabetes results from autoimmune-mediated destruction of β cells. The tyrosine kinase inhibitor imatinib might affect relevant immunological and metabolic pathways, and preclinical studies show that it reverses and prevents diabetes. Our aim was to evaluate the safety and efficacy of imatinib in preserving β-cell function in patients with recent-onset type 1 diabetes.

Alfonso Bellia, Aikaterini Andreadi, Luca Giudice, Sofia De Taddeo, Alessio Maiorino, Ilenia D'Ippolito, Federica Maria Giorgino, Valeria Ruotolo, Maria Romano, Andrea Magrini, Nicola Di Daniele, Paola Rogliani, Davide Lauro

Diabetes Care 2021 July 12